Biogen (NASDAQ:BIIB) reported quarterly earnings of $4.77 per share which beat the analyst consensus estimate of $4.16 by 14.66 percent. This is unchanged from the same period last year. The company reported quarterly sales of $2.51 billion which beat the analyst consensus estimate of $2.47 billion by 1.56 percent. This is a 9.73 percent decrease over sales of $2.78 billion the same period last year.
Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) entered a strategic agreement with Roche Holdings AG (OTC: RHHBY) to
